791012-39-0

Upstream product

• 20781-20-8 2,4-Dimethoxybenzylamine 
• 10314-99-5 benzyl 4-(chlorocarbonyl)piperidine-1-carboxylate 
• 95-00-1 2,4-dichloro-benzenemethanamine 
• 138163-07-2 piperidine-1,4-dicarboxylic acid 1-benzyl ester 4-methyl ester 
• 2971-79-1 isonipecotic acid methyl ester 
• 6850-57-3 2-methoxybenzylamine 
• 73415-77-7 1-benzyloxycarbonyl-4-(N-2,4-dichlorobenzylcarbamoyl)piperidine 
• 1141894-77-0 1,1-dimethylethyl-4-({[(2,4-dichlorophenyl)methyl]amino}carbonyl)-1-piperidinecarboxylate 

Downstream Products

• 1155860-54-0 C₂₂H₂₀Cl₃N₃O₃S 
• 842965-16-6 C₁₈H₁₈Cl₂N₂O₂S 
• 1155860-59-5 C₂₃H₂₈Cl₂N₂O₃S 
• 1155860-37-9 C₃₂H₃₄Cl₄N₄O₆S₂ 
• 1155860-44-8 C₁₉H₁₈Cl₂FN₃O₅S 
• 1155860-45-9 C₂₂H₂₀BrCl₂N₃O₃S 
• 1155860-64-2 C₃₁H₄₄Cl₂N₂O₃S 
• 1155860-69-7 C₂₈H₃₅Cl₂N₃O₄S 
• 1155860-48-2 C₁₇H₁₇Cl₃N₂O₃S₂ 
• 1155860-41-5 C₁₇H₁₇BrCl₂N₂O₃S₂ 
• 1155860-39-1 C₂₂H₂₁Cl₂N₃O₃S 
• 1155860-50-6 C₁₆H₂₂Cl₂N₂O₃S 
• 1155860-43-7 C₁₅H₁₉Cl₃N₂O₃S 
• 1155860-47-1 C₁₉H₁₉Cl₂FN₂O₃S 

Relevant academic research and scientific papers

POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE

The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of s

Discovery of potent non-urea inhibitors of soluble epoxide hydrolase

Soluble epoxide hydrolase (sEH) is a novel target for the treatment of hypertension and vascular inflammation. A new class of potent non-urea sEH inhibitors was identified via high throughput screening (HTS) and chemical modification. IC50s of the most potent compounds range from micromolar to low nanomolar.

NOVEL sEH INHIBITORS AND THEIR USE

The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I:(I) wherein R1, R2, R3, R5, R6, R13, A, B, Y, Z, x, and m

NOVEL sEH INHIBITORS AND THEIR USE

The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula (I) wherein R1, R2, R3, R5a, R6a, A, B, K, L, M, Y, Z, I, an

NOVEL SEH INHIBITORS AND THEIR USE

The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R5a, R6a A, B, Y, x, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

NOVEL SEH INHIBITORS AND THEIR USE

The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula (I): wherein R1, R2, R3, R5a, R6a, A, B, K, L, M, Y, Z, x, a

4-Amino-2-piperidino-quinazolines

Regulators of the cardiovascular system and, in particular, in the treatment of hypertension having the formula STR1 wherein R is lower alkyl; X, is a 3- or 4-position substituent and is --(CH2)n CONR1 R2, --O(C